Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

832
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
832
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

1.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
1.3K
Disorders of Leukocytes01:27

Disorders of Leukocytes

838
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
838
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

1.6K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.6K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

940
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
940
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

952
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
952

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients.

Hematological oncology·2025
Same author

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.

Hematology. American Society of Hematology. Education Program·2024
Same author

Human immunodeficiency virus-associated lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Related Experiment Video

Updated: May 28, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

9.9K

[Non-Hodgkin's lymphomas: a short overview].

S Pudasaini1, M Dreyling2

  • 1Medizinische Klinik und Poliklinik III, LMU Klinikum, Marchioninistraße 15, 81377, München, Deutschland.

Innere Medizin (Heidelberg, Germany)
|February 11, 2025
PubMed
Summary

Non-Hodgkin's lymphomas are diverse immune system cancers. New targeted therapies, including CAR T-cell therapy, are improving treatment outcomes beyond traditional chemotherapy.

Keywords:
Cytostatic agentsImmunotherapyLymphoma, B‑cellLymphoma, T‑cellNeutropenia

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

19.7K

Related Experiment Videos

Last Updated: May 28, 2025

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

9.9K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K
Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
07:52

Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma

Published on: January 9, 2019

19.7K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of cancers originating from immune system's lymphatic cells.
  • NHL are clinically categorized into indolent and aggressive subtypes, impacting prognosis and treatment strategies.

Purpose of the Study:

  • To review the current landscape of Non-Hodgkin's lymphoma classification and treatment.
  • To highlight recent advancements in therapeutic options for NHL.

Main Methods:

  • Literature review of Non-Hodgkin's lymphoma classification.
  • Analysis of treatment goals for indolent versus aggressive lymphoma.
  • Overview of novel therapeutic modalities including targeted and cellular therapies.

Main Results:

  • NHL classification into indolent and aggressive forms guides therapeutic approaches and prognosis.
  • Aggressive lymphomas aim for complete remission via intensive treatment.
  • Indolent lymphomas focus on disease control rather than cure.

Conclusions:

  • Recent therapeutic developments, including targeted therapies and chimeric antigen receptor (CAR) T-cells, have significantly improved outcomes for Non-Hodgkin's lymphoma patients.
  • Novel treatment strategies offer new hope for managing both indolent and aggressive lymphoma subtypes.